IRVINE, CA–(Marketwire – September 23, 2010) –  Sun Healthcare Group, Inc. (NASDAQ: SUNH) (“Sun”) announced today that it intends to refinance its existing senior secured credit facilities with borrowings under a new senior secured credit facility to be entered into by SHG Services, Inc., a subsidiary of Sun (“SHG”). The new senior secured facility is expected to include a $60 million revolving credit facility, a $150 million term loan and a $75 million funded letter of credit facility. The refinancing, which is being undertaken in connection with Sun’s previously announced restructuring, is subject to market and other conditions, and there can be no assurances that these transactions will be consummated.

About Sun Healthcare Group, Inc.

Sun’s subsidiaries provide nursing, rehabilitative and related specialty healthcare services principally to the senior population in the United States. Sun’s core business is providing, through its subsidiaries, inpatient services, primarily through 166 skilled nursing centers, 16 combined skilled nursing, assisted and independent living centers, 10 assisted living centers, two independent living centers and eight mental health centers. On a consolidated basis, Sun has annual revenues of $1.9 billion and approximately 30,000 employees in 46 states. At June 30, 2010, SunBridge centers had 23,209 licensed beds located in 25 states, of which 22,427 were available for occupancy. Sun also provides rehabilitation therapy services to affiliated and non-affiliated centers through its SunDance subsidiary, medical staffing services through its CareerStaff Unlimited subsidiary and hospice services through its SolAmor subsidiary.

In May 2010, Sun announced a plan to restructure its business by separating its real estate assets and its operating assets into two separate publicly traded companies through a series of internal restructurings (the “Restructuring”), subject to the approval of stockholders and other conditions. In connection with the Restructuring, SHG will own and continue to operate all of Sun’s operating subsidiaries, with stockholders of Sun receiving a pro rata distribution of the stock of SHG (the “Separation”). Substantially all of Sun’s currently-owned real estate assets will be owned by Sabra Health Care REIT, Inc., a subsidiary of Sun (“Sabra”) and, immediately after the Separation, Sun will merge into Sabra. Following this merger, SHG will change its name to Sun Healthcare Group, Inc. The common stock of both companies is expected to trade on the NASDAQ Global Select Market. The Restructuring (including the Separation) is expected to be completed in the fourth quarter of 2010.

Forward-Looking Statement

Statements made in this release that are not historical facts are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995) that involve risks and uncertainties and are subject to change at any time. These forward-looking statements may include, but are not limited to, statements containing words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “hope,” “intend,” “may” and similar expressions. Forward-looking statements in this release include all statements regarding our expected future financial position and results of operations, business strategy, the impact of reductions in reimbursements and other changes in government reimbursement programs, the timing and impact of the Separation and transactions related thereto, growth opportunities and plans and objectives of management for future operations. Factors that could cause actual results to differ are identified in the public filings made by Sun with the Securities and Exchange Commission and include changes in Medicare and Medicaid reimbursements; the impact that any healthcare reform legislation will have on our business; our ability to maintain the occupancy rates and payor mix at our healthcare centers; potential liability for losses not covered by, or in excess of, our insurance; the effects of government regulations and investigations; the significant amount of our indebtedness, covenants in our debt agreements that may restrict our activities and our ability to make acquisitions, to incur more indebtedness and to refinance indebtedness on favorable terms; our ability to accomplish the Separation and the transactions related thereto, the impact of the current economic downturn on our business; increasing labor costs and the shortage of qualified healthcare personnel; and our ability to receive increases in reimbursement rates from government payors to cover increased costs. More information on factors that could affect our business and financial results are included in our public filings made with the Securities and Exchange Commission, including our Annual Report on Forms 10-K and Quarterly Reports on Form 10-Q, copies of which are available on Sun’s web site, www.sunh.com. There may be additional risks of which we are presently unaware or that we currently deem immaterial.

The forward-looking statements involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control. We caution investors that any forward-looking statements made by Sun are not guarantees of future performance and are only made as of the date of this release. We disclaim any obligation to update any such factors or to announce publicly the results of any revisions to any of the forward-looking statements to reflect future events or developments.

Additional Information

In connection with the Separation, SHG has filed with the SEC a Registration Statement on Form S-1 and Sabra has filed with the SEC a Registration Statement on Form S-4, each containing an identical proxy statement/prospectus. The definitive proxy statement/prospectus will be mailed to Sun stockholders. Before making any voting or investment decision, Sun stockholders and investors are urged to read the proxy statement/prospectus and other documents filed with the SEC carefully and in their entirety when they become available because they will contain important information about the proposed transactions. Stockholders will be able to obtain these documents free of charge at the SEC’s web site at www.sec.gov. In addition, investors and stockholders of Sun may obtain free copies of the documents filed with the SEC by contacting Sun’s investor relations department at (505) 468-2341 (TDD users, please call (505) 468-4458) or by sending a written request to Investor Relations, Sun Healthcare Group, Inc. 101 Sun Avenue N.E., Albuquerque, N.M. 87109.

Sun and its directors and executive officers and other members of its management and employees may be deemed to be participants in the solicitation of proxies from the stockholders of Sun in connection with the transactions described in this release. Information about the directors and executive officers of Sun and their ownership of shares of Sun common stock are set forth in the Annual Report on Form 10-K for the year ended December 31, 2009, filed with the SEC on March 5, 2010, and in the definitive proxy statement relating to Sun’s 2010 Annual Meeting of Stockholders filed with the SEC on April 30, 2010. These documents can be obtained free of charge from the sources indicated above. Additional information regarding the interests of these participants will also be included in the definitive proxy statement/prospectus when it becomes available.

TAMPA, FL–(Marketwire – September 23, 2010) –  Bacteria breakouts that are surviving the best antibiotics available are spreading across the U.S. at an alarming rate, according to infectious disease experts. 

“Bugs, superbugs, MRSA (methicillin-resistant Staphylococcus aureus) and KPC (Klebsiella pneumoniae carbapenamase) have cropped up in germ-infested health clubs, gyms and even dirty hospitals,” says Dr. Brad Spellberg, infectious disease specialist, scientist, author and researcher at the David Geffen School of Medicine at UCLA and Harbor/UCLA Medical Center in Los Angeles. “Our industry is not developing any new antibiotics to combat this medical urgency.”

Spellberg, a recognized expert on the topic of antibiotic-resistant germs, and other physicians expressed alarm at the lack of antibiotics currently in development while testifying this past June during a U.S. House Energy and Commerce Health Subcommittee special hearing.

Dr. Spellberg, and other physicians who testified, raised concern for the spread of antibiotic-resistant microbes, including out of the hospital and into the community — with lethal results. 

“Everyone is at risk of these infections,” warned Dr. Spellberg, who spoke on behalf of the Infectious Diseases Society of America. Dr. Spellberg is also a member of the Advisory Board of Zimek Technologies, a worldwide leader in infection control and biohazard remediation which has been developing and marketing its proven patented automatic Micro-Mist^® decontamination technologies for more than five years.

Zimek’s industry-leading technologies are used by the U.S. Department of Homeland Security, Department of Defense, Fire and EMS departments, healthcare facilities, public health agencies, transit systems, correctional facilities, and local law enforcement agencies across America. Zimek’s special products “micronize” disinfectants that can quickly and automatically decontaminate facilities, equipment and vehicles. Zimek’s germ-killing, revolutionary “micro-mist” can permeate crevasses and hidden surfaces where super-germs are untouched by standard sanitizing methods.

A dangerous new “superbug” gene created more attention last week. Labeled New Delhi metallo-beta-lactamase, better known as NDM-1, it is a resistant gene proliferating in particular “superbugs” which have the potential of spreading around the world, and scientists say there are almost no drugs in the pipeline to treat it.

Antibiotic-resistant infections “are extremely difficult to treat and frequently recur,” Spellberg said. “These infections result in tremendous pain, suffering and disfigurement in adults, children and infants, and have caused millions of deaths worldwide.”

Nearly 100,000 Americans die annually from infections acquired in hospitals, and treatment-resistant strains are spreading into our health clubs and gyms, Spellberg added.

“Zimek’s proven rapid infection control application is a meaningful 21^st century best practices infection prevention technology which will add another weapon to our arsenal to combat the spread of infectious diseases,” said Kurt Grosman, CEO of Zimek Technologies. 

Spellberg, who is on the frontlines of the infectious disease battle, will discuss these concerns in a special investigative news story on the “CBS Evening News with Katie Couric” scheduled for broadcast on September 27^th and 28^th. (Please visit www.zimek.com for exact airdate/time.)

Spellberg will also be interviewed on an upcoming episode of “The Doctors,” the award-winning syndicated talk show airing daily in the U.S., Canada, Mexico, Ireland, Sweden and Finland. “The Doctors” is distributed domestically and worldwide by CBS Television Distribution. (Please visit www.zimek.com for exact airdate/time.)

WASHINGTON, DC–(Marketwire – September 23, 2010) –  Today, Lance Armstrong, LIVESTRONG(R) founder and chairman, cancer survivor and champion cyclist, made a surprise visit to the pediatric oncology unit at Children’s National Medical Center. He was joined by John R. Seffrin, PhD, chief executive officer of the American Cancer Society, to meet with hospital administrators, doctors and young patients and their families.

Today marks the six month anniversary of the Affordable Care Act. Starting today, several critical provisions of the law begin to take effect. Under the new law, healthcare plan providers cannot discriminate against children with pre-existing conditions. More than nine million children in the United States are currently living without health insurance. Up to 72,000 uninsured children with pre-existing conditions could gain coverage as a result of the new reform.

“Parents already feel the weight of the world on their shoulders when a child is diagnosed with cancer,” said Armstrong. “Insurance and health costs shouldn’t serve as a barrier to receiving quality, timely treatment. I’m hopeful that this reform will save lives and improve the quality of life for the more than 270,000 childhood cancer survivors currently living in the United States.”

“The Affordable Care Act is providing critical protections that are expanding access to lifesaving health care to children and adults with cancer or at risk of cancer,” said Seffrin. “Important provisions taking effect today prohibit health plans from denying coverage to children up to age 19 with pre-existing conditions such as cancer, and enable dependent children to remain on their parent’s insurance policy up to age 26.”

“With advances and breakthroughs in therapy, approximately 75% of children with cancer are cured of their disease. Nevertheless, cancer remains the leading cause of non-accidental death in children in the United States and many survivors suffer from chronic conditions that result from their treatment. Children’s National Medical Center is proud to be a leader in the search for novel treatments that will increase cure rates while decreasing adverse effects,” said Jeffrey S. Dome, MD, PhD; Chief, Division of Oncology; Center for Cancer and Blood Disorders; Children’s National Medical Center.

Armstrong’s visit also falls during National Childhood Cancer Awareness Month, a time to increase awareness and encourage support for the children and families affected by the disease. Cancer is currently the leading cause of death by disease among U.S. children between infancy and age 15, and it is estimated that 10,730 new cases of pediatric cancer were diagnosed in children 0-14 years of age in 2009. Two-thirds of childhood cancer survivors face at least one chronic health condition later in life and one quarter of survivors face a late effect from treatment that is severe or life threatening.

LIVESTRONG, the organization Armstrong established to support fellow cancer survivors and their families, offers a multitude of resources to help pediatric cancer survivors and their families manage the long-term effects of childhood cancers. The organization recently helped establish the LIVESTRONG Childhood Cancer Survivorship Center at Dell Children’s Medical Center in Austin, Texas. The Center aims to improve the health and well-being of childhood cancer survivors by promoting adherence to a schedule of follow-up appointments; providing referrals to specialists; offering psychosocial support groups; transitioning patients to adult care when they are ready; and educating patients, parents and healthcare professionals about the long-term effects of cancer treatment.

LIVESTRONG SurvivorCare also offers specialized resources that focus on the needs of cancer survivors, including children. The free resource, available in English and Spanish, provides survivors and their families with emotional support; individual counseling; financial and legal advice, including finding assistance for the uninsured or underinsured; and matching to clinical trials.

About LIVESTRONG
Founded in 1997 by cancer survivor and champion cyclist Lance Armstrong and based in Austin, Texas, LIVESTRONG fights for the 28 million people around the world living with cancer today. LIVESTRONG connects individuals to the support they need, leverages funding and resources to spur innovation and engages communities and leaders to drive social change. Known for the iconic yellow wristband, LIVESTRONG‘s mission is to inspire and empower anyone affected by cancer. For more information, visit www.LIVESTRONG.org.

About Children’s National Medical Center
Children’s National Medical Center in Washington, DC, has been serving the nation’s children since 1870. Home to Children’s Research Institute and the Sheikh Zayed Institute for Pediatric Surgical Innovation, Children’s National is consistently ranked among the top pediatric hospitals by U.S. News & World Report and the Leapfrog Group. With 283 beds, more than 1,330 nurses, 550 physicians, and seven regional outpatient centers, Children’s National is the only exclusive provider of pediatric care in the Washington metropolitan area. Children’s National has been recognized by the American Nurses Credentialing Center as a Magnet® designated hospital, the highest level of recognition for nursing excellence that a medical center can achieve. For more information, visit www.ChildrensNational.org.

WEST HARTFORD, CT–(Marketwire – September 23, 2010) –  ORLive, the leader in online medical video, presents a live interactive broadcast of a hip replacement surgery featuring technology from Zimmer. On-demand features this month include our library of procedures and educational programming focused on atrial fibrillation. Additionally, ORLive invites you to take part in the latest installment of the Virtual Brain Tumor Board.

NEW ON ORLIVE

LIVE SURGERY VIDEO – Continuum® Acetabular System and Zimmer® M/L Taper with Kinectiv® Technology
Premieres Thursday, September 23, 2010 at 7PM EDT

On Thursday, September 23rd at 7 PM EDT Zimmer Medical Education will broadcast an ORLive Total Hip Arthroplasty featuring the Continuum Acetabular System and the Kinectiv Modular Neck Technology. The surgery will be performed by Dr. Mark Hartzband, Hartzband Center for Hip and Knee Replacement, L.L.C., Paramus, NJ and will be moderated by Dr. Paul Duwelius, St. Vincent Hospital, Portland, OR. The broadcast will last one hour and will show the entire surgical procedure. Following the live broadcast the surgery will be archived for future playback.

This opportunity allows for firsthand insight of the safe and effective implantation and surgical procedure involved with the Continuum® Acetabular System and the Zimmer® M/L Taper with Kinectiv® Technology.

This surgery video is available exclusively to members of the ORLive community, and members can interact and ask questions via the ORLive website. Learn more about this broadcast or get a reminder at ORLive.com, and be ready to view this exciting procedure by activating your free membership to ORLive today.

NOW ON-DEMAND – Artificial Disc Treatments for Cervical Disease
Now Available On-Demand

Until recently, spinal fusion was the surgical solution to cervical disc disease. ORLive invites you to watch footage of an Artificial Discectomy performed by William Kuhn, MD of Halifax Hospital, and join in on a live online discussion with the doctor and patient, Ali Rabatsky. 

Viewers of this video are invited to interact with the team via the ORLive website, where you can also request a reminder to alert you when this video is going live.

ORLIVE REFERRALS – Week of September 20, 2010
September is National Atrial Fibrillation Awareness Month, and each week ORLive highlights on-demand videos for our membership and visitors. 

Medical Education Referral: Paracardioscopic Ex-Maze, from FirstHealth Moore Regional Hospital

CME Referral: Reality EP: Tackling Left Atrial Tachycardias after Catheter Ablation for AF from the Heart Rhythm Society

Viewer’s Referral: Convergent Procedure for Atrial Fibrillation, from FirstHealth Moore Regional Hospital

HIGHLIGHTS

NOW ON-DEMAND – Surgical and Medical Treatments for Type 2 Diabetes
Now Available On-Demand

Type 2 diabetes can lead to potentially deadly complications for many patients, but the team at NewYork-Presbyterian remains on the forefront of research and treatment innovations. Join Dr. Francesco Rubino, Chief, Gastrointestinal Metabolic Surgery at the Weill Cornell Medical Center, Dr. Judith Korner, from Columbia University Medical Center, and Dr. Louis Aronne, from the Weill Cornell Medical Center as they review the advancements that are being made and see what happens when gastric bypass surgery results in a possible remission of diabetes.

Viewers of this video can still interact with the team via the ORLive website, where you can also request updates as they become available.

PREVIEW – Zimmer Patient Specific Instruments and the Gender Solutions™ Natural-Knee® Flex System
Premieres Tuesday, September 28, 2010 at 7PM EDT

On Tuesday, September 28th at 7 PM EST Zimmer Medical Education will broadcast an ORLive Zimmer Patient Specific Instrument surgery featuring Zimmer Patient Specific Instruments and Natural Knee. The surgery will be performed by Dr. Michael Bolognesi, Duke University Medical Center and will be moderated by Dr. Shawn Hocker from Atlantic Orthopedics, PA in Wilmington, NC. The broadcast will last one hour and will show the entire surgical procedure.

This surgery video is available exclusively to members of the ORLive community, and members can interact and ask questions via the ORLive website. Learn more about this broadcast or get a reminder at ORLive.com, and be ready to view this exciting procedure by activating your free membership to ORLive today.

About ORLive
ORLive is the leading provider of video communication channels to the healthcare community. Working collaboratively with hospitals and device manufacturers, ORLive produces and distributes customized, interactive, video programs that demonstrate the latest advances in medicine, surgical techniques and product innovations. The ORLive broadcasting network provides an intimate look at over 650 live and on-demand surgeries to a global audience, streaming over 50,000 hours of programming each month. The ORLive network can be found on-line at www.ORLive.com.

id=”nav_links”>

ALEXANDRIA, VA–(Marketwire – September 23, 2010) –   Today, the Food and Drug Administration (FDA) announced that it will significantly restrict the use of the diabetes drug Avandia and other drugs containing rosiglitazone to patients with Type 2 diabetes who cannot control their diabetes on other medications. These new restrictions are in response to data that suggest an elevated risk of cardiovascular events, such as heart attack and stroke, in patients treated with Avandia.

The FDA, in its announcement, noted that it will require GlaxoSmithKline (GSK) to develop a restricted access program for Avandia under a risk evaluation and mitigation strategy (REMS). Under the REMS, Avandia will be available to new patients only if they are unable to achieve glucose control on other medications and are unable to take Actos (pioglitazone), the only other drug in this class. Current users of Avandia who are benefiting from the drug will be able to continue using the medication if they choose to do so. Doctors will have to attest to and document their patients’ eligibility; patients will have to review statements describing the cardiovascular safety concerns associated with this drug and acknowledge they understand the risks. The agency anticipates that the REMS will limit use of Avandia significantly.

The European Medicines Agency (EMA) has suspended the marketing authorization for all rosiglitazone-containing medicines (Avandia, Avandamet® and Avaglim®). These medicines will no longer be available in Europe within the next few months.

The American Diabetes Association, The Endocrine Society and the American Association of Clinical Endocrinologists urge patients who are currently taking Avandia or any combination pill that includes Avandia to contact their diabetes care provider’s office for instructions about treatment options. Patients should be aware that stopping a diabetes medication without consulting a doctor can result in higher levels of blood glucose that may cause serious short term health problems and could increase the risk of long term diabetes-related complications.

Patients and health care professionals should also be aware that multiple classes of drugs, often with more than one agent per class, are available to achieve and maintain glucose control in type 2 diabetes. In order to limit the risk of long-term complications, optimal glucose control, along with control of other risk factors, such as high blood pressure and cholesterol, is critically important for patients with type 2 diabetes. A number of other medications can be used to control diabetes and should be discussed with a patient’s health care team. For more information on the different classes of available medications drugs: http://www.diabetes.org/living-with-diabetes/treatment-and-care/medication/oral-medications/what-are-my-options.html.

The American Diabetes Association, The Endocrine Society, and American Association of Clinical Endocrinologists continue to support the FDA in its role as the regulatory agency that makes decisions regarding drug safety and efficacy.

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

Founded in 1916, The Endocrine Society is the world’s oldest, largest and most active organization devoted to research on hormones and the clinical practice of endocrinology. Today, The Endocrine Society’s membership consists of over 14,000 scientists, physicians, educators, nurses and students in more than 100 countries. Society members represent all basic, applied, and clinical interests in endocrinology. The Endocrine Society is based in Chevy Chase, Maryland. To learn more about the Society and the field of endocrinology, visit our site at www.endo-society.org.

AACE is the world’s largest professional medical organization of clinical endocrinologists with more than 6,500 members in the United States and 91 other countries. AACE members are physicians who specialize in endocrinology, diabetes, and metabolism. For more information about AACE, visit our Web site at www.aace.com, become a fan on Facebook at www.facebook.com/theaace or follow us on Twitter at www.twitter.com/theaace. 

id=”nav_links”>

PARIS–(Marketwire – September 23, 2010) – First half-year Financial Information as of June30, 2010

IFRS – Regulated information – Audited

Cegedim: Half-year net profit up 15.6% to ?19.9 million

First half 2010 marked by a strong dynamic commercial performance

Paris, September 23, 2010 – Cegedim, a global technology and services company specializing in the healthcare field, announces consolidated net profit of ?19.9 million for the first half of 2010, up 15.6% over the year-earlier period.

The first half was marked by numerous commercial successes, proving that Cegedim’s range of products and services is well suited to market demand, and that its recent acquisitions hold great promise.

– Simplified income statement

+-------------------------+---------+-------+-------+---------+---------+
|                         |  H1 2010|       |       |  H1 2009|         |
+-------------------------+---------+-------+-------+---------+---------+
|?M                       |        %|       |     ?M|        %|         |
+-------------------------+---------+-------+-------+---------+---------+
|Revenues                 |    448.8|       |  433.9|         |    +3.4%|
+-------------------------+---------+-------+-------+---------+---------+
|EBITDA from ordinary     |     84.1|       |   88.3|         |    -4.7%|
|activities               |         |       |       |         |         |
+-------------------------+---------+-------+-------+---------+---------+
|Depreciation             |    -33.5|       |  -34.2|         |    -2.0%|
+-------------------------+---------+-------+-------+---------+---------+
|Operating profit from    |     50.6|  11.3%|   54.1|    12.5%|    -6.4%|
|ordinary activities      |         |       |       |         |         |
+-------------------------+---------+-------+-------+---------+---------+
|Other exceptional        |     -5.4|       |   -4.7|         |   +17.0%|
|operating revenues /     |         |       |       |         |         |
|expenses                 |         |       |       |         |         |
+-------------------------+---------+-------+-------+---------+---------+
|Operating profit         |     45.2|  10.1%|   49.4|    11.4%|    -8.6%|
+-------------------------+---------+-------+-------+---------+---------+
|Net cost of financial    |    -21.6|       |  -29.8|         |   -27.6%|
|debt                     |         |       |       |         |         |
+-------------------------+---------+-------+-------+---------+---------+
|Tax expenses             |     -4.1|       |   -2.7|         |  +49.1% |
+-------------------------+---------+-------+-------+---------+---------+
|Share of earnings of     |      0.4|       |    0.4|         |     n s |
|equity-accounted         |         |       |       |         |         |
|affiliates               |         |       |       |         |         |
+-------------------------+---------+-------+-------+---------+---------+
|Consolidated net profit  |     19.9|       |   17.2|         |   +15.6%|
+-------------------------+---------+-------+-------+---------+---------+
|Group share of net profit|     19.8|       |   17.2|         |   +15.2%|
+-------------------------+---------+-------+-------+---------+---------+

Consolidated H1 2010 revenues amounted to ?448.8 million, up 0.4% like for like* and 3.4% on a reported basis. As expected, second-quarter growth of 3.8% like for like* and 8.0% on a reported basis offset the first-quarter decline.

The fact that every Group sector made a positive contribution to revenue growth in the second quarter, both like for like* and on a reported basis, is proof of Cegedim’s dynamic sales performance.

Operating profit from ordinary activities came to ?50.6 million, down 6.4% compared with the first half of 2009. This dip is attributable to an increase in personnel costs, which rose 6.2% due to delays implementing certain large-scale CRM projects.

Thus, margin decreased from 12.5% to 11.3%, despite a fine improvement in Healthcare Professionals and Insurance and services sector margins.

Consolidated net profit rose 15.6% compared with a year earlier to ?19.9 million. The biggest contribution to the increase came from lower interest charges on debt, which fell from ?21.4 million to ?10.6 million due to a drop in the average level of outstanding financial debt.

Consolidated net profit attributable to the Group amounted to ?19.8 million, a 15.2% increase over the first half of 2009. Earnings per share amounted to ?1.4, against ?1.8 last year. The increase of the number of shares following the ?180.5 million capital issue of December 2009 explains the drop in EPS.

Sector business trends

– CRM and strategic data

In the first half of 2010, sector revenues rose 3.5% on a reported basis to ?249.1 million. Currency effects and acquisitions helped boost revenues by 1.9% and 2.9% respectively over the first half. Like-for-like revenues fell slightly, by 1.4%. As expected, the 4.8% rise in Q2 revenues helped offset the drop in Q1 caused by delays in executing certain large-scale projects.

One impact of these delays was an increase in personnel costs, which hurt the sector’s operating margin. The sector’s operating profit from ordinary activities was ?18.3 million, down ?6.0 million compared with H1 2009. As a result, operating margin from ordinary activities was 7.3%, versus 10.1% a year earlier.

Second-quarter revenues testify to the sector’s substantial sales momentum, successful geographic expansion of new services, and the beneficial impact of launching new Mobile Intelligence offerings – particularly the SaaS version – with both current and new clients.

Able to integrate SK&A both operationally and commercially in just six months, Cegedim is now fully profiting from the successful strengthening of its OneKey offering in the USA.

These performances lend credence to the Group’s strategic choices: a global presence as a result of the Dendrite acquisition, particularly in rapidly growing markets such as emerging countries; expanding platforms (iPad® and iPhone®, BlackBerry®, etc.); a richer compliance offering in Europe; bringing Dendrite’s business model in line with that of Cegedim (services vs. licenses); and continuing to make substantial investments in R&D to support new products.

The strategic data activity posted a clear rebound in its revenues and profitability in the second quarter. The Group expects this trend to continue in the months ahead.

– Healthcare professionals

Sector first-half 2010 revenues were ?138.7 million, up 0.8% on a reported basis and stable on a like-for-like* basis. Growth of 1.3% in the second quarter offset the slight first-quarter decline, as expected.

Currency effects and acquisitions boosted first-half revenues by 0.5% and 0.4% respectively.

Operating profit from ordinary activities rose 4.2% to ?23.8 million, reflecting a sizeable 60bp increase in the margin to 17.2%. This result is especially remarkable considering that the sector margin was hurt by the wait-and-see attitude of UK physicians and the expected drop in Cegelease’s margin.

The Group continues to generate impressive performances in France, Spain and Italy. In the UK, Cegedim is convinced that it is in a position to profit from new opportunities arising from a reorganization of the UK healthcare system over the coming years.

Lastly, we note that the RMI (paramedic software) and RNP activities (promotional information for pharmacists) continue to turn in very fine performances in terms of revenues and profitability.

After the close of the first-half financial statements, Cegedim’s acquired Pulse, a US company specializing in electronic healthcare records (EHR) management. In the second half, this move will propel the Cegedim Healthcare Software division onto the global stage, positioning the division to capitalize on the considerable new opportunities in this market. For more information on the deal, please see the “Important post-closing transactions and events” section on page 5.

– Insurance and services

Sector revenues rose 9.9% on both a like-for-like* and a reported basis to ?61 million. Insurance and services activities continued to grow by nearly 6% like for like* following an exceptional first quarter.

As expected, operating margin on ordinary activities rose substantially, up 150bp from 12.5% to 14.0%. Operating profit from ordinary activities amounted to ?8.5 million, a 23% increase over the same period in 2009.

These excellent performances are proof that Cegedim’s range of software (Activ’Infinite) and services (various data flow management platforms) is well suited to a rapidly evolving health insurance sector, in which differentiation and productivity gains are crucial.

It is also worth noting the robust trend in the sales of Cegedim SRH, which specializes in the services associated with outsourcing payroll and HR management. Its revenues rose by more than 12% in the first half of 2010, and its profitability improved.

Financial resources

At June 30, 2010, Cegedim’s consolidated total balance sheet amounted to ?1,535 billion, a 15.6% jump over the year-earlier period.

The Group has a robust balance sheet position, with share capital representing 37% of total asset, a 20% increase.

Acquisition goodwill was ?713 million, compared with ?613 million at the end of 2009. This represents 46% of the total balance sheet, which is the same level as six months prior. These trends are attributable chiefly to currency exchange rate and acquisitions.

Cash and equivalents exceed short-term financial debt (less than 1 year).

Netfinancial debt amount to ?443 million compared with ?395 million six months earlier. As expected this increase is due to the use of Cegedim credit revolver facility in order to finance ac quisitions and to the negative evolution of the dollar against the euro.

After the net cost of financial debt and taxes, cash flow was ?51.4 million, on a par with that of the first half of 2009. Gearing level remains unchanged at 0.9 against 0.8 six months earlier.

Working capital requirement increased by ?6.6 million, mainly due to the change in customer receivables. These trends reflect seasonal effects on the Group’s working capital requirement.

At the end of June 2010, the Group complied with all its bank covenants.

First-half highlights

On January 7, 2010, the Group acquired US company SK&A Information Services, Inc., a top-notch supplier of healthcare data. The acquisition strengthens Cegedim’s OneKey offering in the US. Created 26 years ago, SK&A has built and maintains a database with targeted information on more than 2 million healthcare professionals, including more than 800,000 prescribing physicians. This is the only database of US prescribing physicians and other healthcare professionals for which every single email address has been verified by phone contact. The acquired businesses generate full-year revenues of roughly $15 million. Its operational and commercial integration, which was completed in less than 6 months, was a complete success.

On June 3, 2010, Cegedim finalized the acquisition of Swiss CRM and direct marketing businesses from IMS Health to complement and strengthen its existing Swiss offerings. The CRM and Direct Marketing Direct business unit of IMS Health GmbH has been targeting the life science industry in Switzerland for more than a decade and is recognized for its quality and reliability by more than 500 users and 30 companies. The acquired businesses will contribute to the Group’s consolidated result from Q2 2010. Cegedim expects the acquired company to contribute annual revenues in the region of ?2 million.

Moreover, the Group announced on June 18, 2010 the acquisition of French company Hosta, a specialist in third-party management in which it has held a minority stake since 2004. Managing 400,000 beneficiaries and boasting extensive experience in third-party management of health and personal protection insurance policies, Hosta is among France’s leading third-party management companies. This acquisition expands Cegedim Group’s portfolio of solutions dedicated to all of its clients in the insurance sector. The acquired businesses represent annual revenues of approximately ?11 million.

These three deals were financed by internal financing and will not prevent the Group from respecting its debt covenants. Under the agreements signed by the parties, all other terms of the transactions are confidential.

Significant post-closing transactions and events

– Extension of the average maturity of the debt

As part of its policy of diversifying and extending the average maturity of its debt, Cegedim (BB+ S&P), completed on July 27 issuance of a ?300 million bond maturing in 2015, with a fixed annual coupon of 7.00% payable every six months. The strong demand generated by the operation, finalized in just half a day, the quality of the interested parties, and geographic diversity of the investors – of which 70% were located outside of France – enabled Cegedim to raise the ?300 million under favorable conditions. At the same time, the debt issue demonstrates Cegedim’s ability to tap financial markets.

– External growth

On July 27 Cegedim finalized the acquisition of Pulse Systems, Inc., a leading US healthcare software and services supplier. The move gives Cegedim access to the US market for the computerization of healthcare professionals at a very critical time for the Electronic Health Records (EHR) and Practice Management (PM) software markets.

Founded in 1997, Pulse Systems has developed an extremely sophisticated and scalable ambulatory healthcare IT solution – Pulse Patient Relationship Management. This solution includes EHR, PM, e-Prescribing, Revenue Cycle Management services, etc. The company is based in Wichita and has more than 100 employees. Pulse is profitable and will likely continue to grow in a rapidly expanding sector: it expects to increase its revenues more than four-fold by 2014.

Building on the Target Software acquisition in 2005, the Dendrite acquisition in 2007 and the SK&A acquisition earlier this year, this new addition in the US is squarely in line with the Group’s global strategy. It will enable the Group to leverage its complementary activities in North America and transform its European Cegedim Healthcare Software division into a global player by utilizing the Pulse solutions to expand its presence in the US market.

Cegedim finalized the acquisition of Deskom a leading French B-to-B invoice dematerialization company, on September 6th. The deal is an opportunity for Cegedim EDI, its professional electronic data management department, to build on its leadership in the field.

The Deskom acquisition allows Cegedim EDI, the healthcare data exchange leader, to move ahead with its strategy of opening its services to all business sectors and becoming Europe’s top electronic invoicing network, able to handle any request regardless of invoice volumes, project complexity, or the number of countries involved.

These activities represent annual revenues of around ?4 million and will be part of the consolidation scope of Cegedim Group for H2 2010.

These two deals were financed by internal financing. Under the agreements signed by the parties, all other terms of the transactions are confidential.

– New trademark strategy and visual identity for the Group

In order to strengthen its image, Cegedim Management decided to simplify the brand’s visual identity for the Group and its main healthcare Business Units. Each Business Unit’s logo and name will reflect a key description of its overall activity. Therefore, Cegedim Dendrite has been renamed Cegedim Relationship Management.

This change is inspired by the Group’s desire to present its customers with a more coherent, unified image of all of its businesses and to succinctly convey its commitment to providing them with the most advanced products and services in the industry. It is also a way of expressing the successful integration of Dendrite, as the new visual identity will incorporate some graphic elements from its logo.

These changes will take place gradually starting on September 24, 2010. An analysis of the possible accounting consequences of canceling the Dendrite trademark are still under way.

As part of its new brand strategy and to simplify and modernize this window on the Group, Cegedim will launch its new corporate website: www.cegedim.com This new, redesigned portal does more to emphasize the Group’s various activities and gives users direct access to the sites of its Business Units, while incorporating traditional sections on Recruitment, Press and Finance.

2010 outlook

Acquisitions made during the first half-year, as well as the post-closing acquisitions of Pulse and Deskom, are in line with the external growth policy the Group presented at the time of the December 2009 capital increase. These acquisitions did not prevent the Group from meeting all of its covenants. We recall that the sole purpose of the bond issue for ?300 million on July 27, 2010, was to refinance existing bank debt.

Given its adaptability, good regional mix and business mix of revenues, commercial momentum and half-year performances, the Group confirms its goal to consolidate leadership in the global healthcare market with revenue growth of approximately 5% for 2010

Based on its half-year results, the Group is no longer aiming for margin improvement for 2010.

Financial calendar

+-------------------------+--------------------+--------------------+
|The Group will hold a    |                    |                    |
|conference call this     |                    |                    |
|evening (September 23) at|                    |                    |
|6:15 pm in French and    |                    |                    |
|7:00 pm in English at the|                    |                    |
|following numbers (Paris |                    |                    |
|time):                   |                    |                    |
+-------------------------+--------------------+--------------------+
|                         |· From France: 01 72|Access code:        |
|                         |30 02 03            |13648531            |
+-------------------------+--------------------+--------------------+
|                         |· From UK: 1616 018 |#                   |
|                         |915                 |                    |
+-------------------------+--------------------+--------------------+
|                         |· From the US: 703  |                    |
|                         |62 19 122           |                    |
+-------------------------+--------------------+--------------------+
+-------------------------+--------------------+--------------------+

September 24, 2010

– SFAF Meeting – 24 rue de Penthièvre 75008 Paris (at 10:00am)

– Half-year Financial Report (after the stock market closes)

From September 27 to October 15, 2010

– Roadshow in Europe

From October 4 to October 8, 2010

– Roadshow in the US

November 15, 2010

– Q3 revenues announcement (after the stock market closes)

Additional information

The Board of Directors and the Auditors met on September 23, 2010, to approve 2010 Half-year consolidated financial statements. Audit procedures have been performed and the 2010 Half-year statutory auditors’ report on the consolidated financial statements is forthcoming.

The financial information presented in this press release comes from Cegedim half year consolidated financial statements and is fully available on the 2010 Half-year Financial Report at www.cegedim.fr/finance as of September 24, 2010.

A presentation of Cegedim 2010 Half-year results is also available on the Website.

Appendices

– Revenues by sector and by quarter#:

# Figures rounded to the nearest unit.

Year 2010

+-------------------------+---------+---------+----+----+---------+
|? thousands              |    Q1   |    Q2   |  Q3|  Q4|   Total |
+-------------------------+---------+---------+----+----+---------+
|CRM and strategic data   |  111,532|  137,575|    |    |  249,107|
+-------------------------+---------+---------+----+----+---------+
| Healthcare professionals|   64,461|   74,278|    |    |  138,739|
+-------------------------+---------+---------+----+----+---------+
|Insurance and services   |   29,627|   31,364|    |    |   60,991|
+-------------------------+---------+---------+----+----+---------+
|Group                    |  205,620|  243,217|    |    |  448,837|
+-------------------------+---------+---------+----+----+---------+
+-------------------------+---------+---------+----+----+---------+

Year 2009 pro-forma

For information, Revenues at June 30, 2009 were restated between sectors for an amount of ?4.4 million. In order to continue streamlining the Group’s structure, certain activities of the Healthcare professionals and Insurance and services sectors have been linked to entities of the CRM and strategic data sector. Pro-forma revenue is mentioned below.

+-------------------------+---------+---------+---------+---------+---------+
|? thousands              |    Q1   |    Q2   |    Q3   |    Q4   |   Total |
+-------------------------+---------+---------+---------+---------+---------+
|CRM and strategic data   |  117,523|  123,223|  117,178|  140,361|  498,285|
+-------------------------+---------+---------+---------+---------+---------+
| Healthcare professionals|   65,247|   72,411|   58,779|   67,817|  264,254|
+-------------------------+---------+---------+---------+---------+---------+
|Insurance and services   |   25,892|   29,609|   22,062|   33,970|  111,533|
+-------------------------+---------+---------+---------+---------+---------+
|Group                    |  208,662|  225,245|  198,017|  242,148|  874,072|
+-------------------------+---------+---------+---------+---------+---------+
+-------------------------+---------+---------+---------+---------+---------+

– By sector of activity and currency, the distribution of revenues for the first half-year of 2010 is as follows:

+-------------------------+------+-----+-----+--------+
|                         |  Euro|  USD|  GBP|  Others|
+-------------------------+------+-----+-----+--------+
|CRM and strategic data   |   51%|  23%|   4%|     22%|
+-------------------------+------+-----+-----+--------+
| Healthcare professionals|   80%|    -|  20%|       -|
+-------------------------+------+-----+-----+--------+
|Insurance and services   |   99%|    -|    -|      1%|
+-------------------------+------+-----+-----+--------+
|Group                    |   66%|  13%|   9%|     12%|
+-------------------------+------+-----+-----+--------+
+-------------------------+------+-----+-----+--------+

– By sector of activity and geographic zone, the distribution of revenues for the first half-year of 2010 is as follows:

+-------------------------+--------+------------------+---------------+
|                         |  France|  Europe ex France|  North America|
+-------------------------+--------+------------------+---------------+
|CRM and strategic data   |     31%|               33%|            24%|
+-------------------------+--------+------------------+---------------+
| Healthcare professionals|     77%|               23%|              -|
+-------------------------+--------+------------------+---------------+
|Insurance and services   |     99%|                 -|              -|
+-------------------------+--------+------------------+---------------+
|Group                    |     55%|               26%|            13%|
+-------------------------+--------+------------------+---------------+
+-------------------------+--------+------------------+---------------+

+-------------------------+-------------------+
|                         |  Rest of the world|
+-------------------------+-------------------+
|CRM and strategic data   |                12%|
+-------------------------+-------------------+
| Healthcare professionals|                  -|
+-------------------------+-------------------+
|Insurance and services   |                 1%|
+-------------------------+-------------------+
|Group                    |                 7%|
+-------------------------+-------------------+
+-------------------------+-------------------+

– Consolidated first-half financial statements

Assets

+-------------------------+------------+------------+
|? thousands              |  06/30/2010|  06/30/2009|
+-------------------------+------------+------------+
|Goodwill on acquisition  |     713,179|     613,342|
+-------------------------+------------+------------+
|Development costs        |      31,057|      57,644|
+-------------------------+------------+------------+
|Trademarks, patents      |     135,868|     104,810|
+-------------------------+------------+------------+
|Other intangible fixed   |     106,145|      63,192|
|assets                   |            |            |
+-------------------------+------------+------------+
|Intangible fixed assets  |     273,070|     225,646|
+-------------------------+------------+------------+
|Property                 |         446|         417|
+-------------------------+------------+------------+
|Buildings                |       6,168|       6,225|
+-------------------------+------------+------------+
|Plant, machinery and     |      24,940|      24,377|
|equipment                |            |            |
+-------------------------+------------+------------+
|Other tangible fixed     |      13,866|      13,969|
|assets                   |            |            |
+-------------------------+------------+------------+
|Construction work in     |          35|         234|
|progress                 |            |            |
+-------------------------+------------+------------+
|Tangible fixed assets    |      45,456|      45,221|
+-------------------------+------------+------------+
|Equity investments       |         295|         302|
+-------------------------+------------+------------+
|Loans                    |         555|         551|
+-------------------------+------------+------------+
|Other fixed financial    |       9,103|       8,030|
|assets                   |            |            |
+-------------------------+------------+------------+
|Fixed financial assets ? |       9,953|       8,883|
|excluding shares of      |            |            |
|equity-accounted         |            |            |
|affiliates               |            |            |
+-------------------------+------------+------------+
|Shares of                |       6,811|       7,173|
|equity-accounted         |            |            |
|affiliates               |            |            |
+-------------------------+------------+------------+
|Government ? Deferred tax|      42,476|      33,350|
+-------------------------+------------+------------+
|Accounts receivable:     |      16,056|      15,282|
|long-term portion        |            |            |
+-------------------------+------------+------------+
|Other receivables:       |       2,064|         983|
|long-term portion        |            |            |
+-------------------------+------------+------------+
|Non-current assets       |   1,109,064|     949,881|
+-------------------------+------------+------------+
|Services in progress     |         188|         200|
+-------------------------+------------+------------+
|Goods                    |      11,005|      10,956|
+-------------------------+------------+------------+
|Advances and deposits    |       1,882|       1,172|
|received on orders       |            |            |
+-------------------------+------------+------------+
|Accounts receivable:     |     226,488|     210,502|
|short-term portion       |            |            |
+-------------------------+------------+------------+
|Unpaid, called-up capital|           -|           -|
+-------------------------+------------+------------+
|Other receivables:       |      20,533|      18,413|
|short-term portion       |            |            |
+-------------------------+------------+------------+
|Cash equivalents         |       1,159|      30,630|
+-------------------------+------------+------------+
|Cash                     |     141,814|      90,739|
+-------------------------+------------+------------+
|Prepaid expenses         |      22,936|      15,847|
+-------------------------+------------+------------+
|Current assets           |     426,006|     378,461|
+-------------------------+------------+------------+
|Total assets             |   1,535,070|   1,328,341|
+-------------------------+------------+------------+

Liabilities

+-------------------------+------------+------------+
|? thousands              |  06/30/2010|  06/30/2009|
+-------------------------+------------+------------+
|Share capital            |      13,337|      13,337|
+-------------------------+------------+------------+
|Issue premium            |     185,562|     185,562|
+-------------------------+------------+------------+
|Group reserves           |     294,967|     249,732|
+-------------------------+------------+------------+
|Group translation        |        -238|        -238|
|reserves                 |            |            |
+-------------------------+------------+------------+
|Group translation        |      46,317|     -37,844|
|gains/losses             |            |            |
+-------------------------+------------+------------+
|Group earnings           |      19,849|      54,719|
+-------------------------+------------+------------+
|Investment subsidies     |           -|           -|
+-------------------------+------------+------------+
|Regulated provisions     |           -|           -|
+-------------------------+------------+------------+
|Shareholders? equity,    |     559,794|     465,267|
|Group share              |            |            |
+-------------------------+------------+------------+
|Minority interests       |         383|         609|
|(reserves)               |            |            |
+-------------------------+------------+------------+
|Minority interests       |          72|         114|
|(earnings)               |            |            |
+-------------------------+------------+------------+
|Minority interests       |         455|         724|
+-------------------------+------------+------------+
|Shareholders? equity     |     560,249|     465,991|
+-------------------------+------------+------------+
|Long-term financial      |     453,067|     391,408|
|liabilities              |            |            |
+-------------------------+------------+------------+
|Long-term financial      |      10,707|      16,517|
|instruments              |            |            |
+-------------------------+------------+------------+
|Deferred tax liabilities |      60,298|      51,394|
+-------------------------+------------+------------+
|Non-current provisions   |      28,534|      21,517|
+-------------------------+------------+------------+
|Other non-current        |      12,396|       9,550|
|liabilities              |            |            |
+-------------------------+------------+------------+
|Non-current liabilities  |     565,002|     490,386|
+-------------------------+------------+------------+
|Short-term financial     |     142,671|     133,621|
|liabilities              |            |            |
+-------------------------+------------+------------+
|Short -term financial    |           -|           -|
|instruments              |            |            |
+-------------------------+------------+------------+
|Accounts payable and     |      71,813|      73,604|
|related accounts         |            |            |
+-------------------------+------------+------------+
|Tax and social           |     119,088|     113,705|
|liabilities              |            |            |
+-------------------------+------------+------------+
|Provisions               |       6,116|       7,133|
+-------------------------+------------+------------+
|Other current liabilities|      70,131|      43,902|
+-------------------------+------------+------------+
|Current liabilities      |     409,819|     371,965|
+-------------------------+------------+------------+
|Total liabilities        |   1,535,070|   1,328,341|
+-------------------------+------------+------------+

– Income statement

+-------------------------+------------+------------+
|? thousands              |  06/30/2010|  06/30/2009|
+-------------------------+------------+------------+
|Revenues                 |     448,837|     433,906|
+-------------------------+------------+------------+
|Other income from        |           -|           -|
|business activities      |            |            |
+-------------------------+------------+------------+
|Capitalized production   |      15,186|      16,616|
+-------------------------+------------+------------+
|Purchased consumed       |     -48,637|     -47,729|
+-------------------------+------------+------------+
|External expenses        |    -110,205|    -106,409|
+-------------------------+------------+------------+
|Taxes                    |      -7,069|      -6,503|
+-------------------------+------------+------------+
|Payroll costs            |    -213,954|    -201,391|
+-------------------------+------------+------------+
|Depreciation expenses    |     -33,494|     -34,179|
+-------------------------+------------+------------+
|Provision expenses and   |         -69|         391|
|write-backs              |            |            |
+-------------------------+------------+------------+
|Change in inventories of |         -20|         -63|
|in-progress and finished |            |            |
|products                 |            |            |
+-------------------------+------------+------------+
|Other operating income   |          49|        -560|
|and expenses             |            |            |
+-------------------------+------------+------------+
|Operating profit from    |      50,624|      54,079|
|ordinary activities      |            |            |
+-------------------------+------------+------------+
|Other non-current        |      -5,448|      -4,657|
|operating income and     |            |            |
|expenses                 |            |            |
+-------------------------+------------+------------+
|Operating profit         |      45,175|      49,422|
+-------------------------+------------+------------+
|Income from cash and cash|         564|         829|
|equivalents              |            |            |
+-------------------------+------------+------------+
|Gross cost of financial  |     -12,283|     -20,304|
|debt                     |            |            |
+-------------------------+------------+------------+
|Other financial income   |      -9,866|     -10,349|
|and expenses             |            |            |
+-------------------------+------------+------------+
|Net cost of financial    |     -21,585|     -29,824|
|debt                     |            |            |
+-------------------------+------------+------------+
|Income taxes             |     -16,134|      -3,005|
+-------------------------+------------+------------+
|Deferred income taxes    |      12,069|         279|
+-------------------------+------------+------------+
|Tax expenses             |      -4,065|      -2,726|
+-------------------------+------------+------------+
|Share of earnings of     |         396|         368|
|equity-accounted         |            |            |
|affiliates               |            |            |
+-------------------------+------------+------------+
|Consolidated net profit  |      19,921|      17,240|
+-------------------------+------------+------------+
|Group share (A)          |      19,849|      17,237|
+-------------------------+------------+------------+
|Minority interests       |          72|           3|
+-------------------------+------------+------------+
|Average number of shares |  13,963,775|   9,331,449|
|excl. Treasury stocks (B)|            |            |
+-------------------------+------------+------------+
|Earnings per share -     |         1.4|         1.8|
|euros (A/B)              |            |            |
+-------------------------+------------+------------+
|Dilutive instruments     |           -|           -|
+-------------------------+------------+------------+
|Diluted earnings per     |         1.4|         1.8|
|share - euros            |            |            |
+-------------------------+------------+------------+

– Cash flow statement

+-------------------------+------------+------------+
|? thousands              |  06/30/2010|  06/30/2009|
+-------------------------+------------+------------+
|Consolidated net profit  |      19,921|      17,240|
+-------------------------+------------+------------+
|Share of earnings of     |        -396|        -368|
|equity-accounted         |            |            |
|affiliates               |            |            |
+-------------------------+------------+------------+
|Depreciation and         |      31,885|      34,411|
|amortization expense     |            |            |
+-------------------------+------------+------------+
|Capital gain or losses on|         -33|         275|
|disposals                |            |            |
+-------------------------+------------+------------+
|Cash flow after net cost |      51,377|      51,558|
|of financial debt and    |            |            |
|taxes                    |            |            |
+-------------------------+------------+------------+
|Net cost of financial    |      21,585|      29,824|
|debt                     |            |            |
+-------------------------+------------+------------+
|Tax expenses             |       4,065|       2,726|
+-------------------------+------------+------------+
|Cash flow before net cost|      77,027|      84,108|
|of financial debt and    |            |            |
|taxes                    |            |            |
+-------------------------+------------+------------+
|Tax paid                 |      -9,368|         245|
+-------------------------+------------+------------+
|Plus: change in operating|     -17,759|     -11,179|
|working capital          |            |            |
|requirement              |            |            |
+-------------------------+------------+------------+
|Net cash from operations |      49,900|      73,174|
|(A)                      |            |            |
+-------------------------+------------+------------+
|Acquisitions of          |     -18,160|     -20,044|
|intangible fixed assets  |            |            |
+-------------------------+------------+------------+
|Acquisitions of tangible |     -13,045|     -12,098|
|fixed assets             |            |            |
+-------------------------+------------+------------+
|Acquisitions of financial|           -|      -1,454|
|assets                   |            |            |
+-------------------------+------------+------------+
|Disposals of tangible and|       2,074|       2,263|
|intangible fixed assets  |            |            |
+-------------------------+------------+------------+
|Disposals of financial   |         124|         363|
|assets                   |            |            |
+-------------------------+------------+------------+
|Impact of changes in     |     -25,680|      -2,691|
|consolidation scope      |            |            |
+-------------------------+------------+------------+
|Dividends from equity    |           -|           -|
|accounted affiliates     |            |            |
+-------------------------+------------+------------+
|Net cash from investment |     -54,687|     -33,661|
|operations (B)           |            |            |
+-------------------------+------------+------------+
|Dividends paid to parent |           -|           -|
|company shareholders     |            |            |
+-------------------------+------------+------------+
|Dividends paid to the    |           -|           -|
|minority interests of    |            |            |
|consolidated companies   |            |            |
+-------------------------+------------+------------+
|Increase in cash capital |           -|           -|
+-------------------------+------------+------------+
|Debt issued              |      61,611|      62,240|
+-------------------------+------------+------------+
|Debt reimbursements      |     -57,587|     -86,091|
+-------------------------+------------+------------+
|Interest paid on debts   |     -10,606|     -21,435|
+-------------------------+------------+------------+
|Other financial income   |      -8,073|      -2,675|
|and expenses             |            |            |
+-------------------------+------------+------------+
|Net cash from financing  |     -14,655|     -47,961|
|operations ©           |            |            |
+-------------------------+------------+------------+
|Change in cash (A+B+C)   |     -19,442|      -8,448|
+-------------------------+------------+------------+
|Opening cash position    |     102,338|      70,254|
+-------------------------+------------+------------+
|Closing cash position    |      89,379|      61,539|
+-------------------------+------------+------------+
|Foreign exchange gains or|      -6,483|         267|
|losses                   |            |            |
+-------------------------+------------+------------+

*at constant scope and exchange rates

About Cegedim: Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, life sciences companies, healthcare professionals and insurance companies. The world leader in life sciences CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs 8,600 people in more than 80 countries and generated revenue of ?874 million in 2009. Cegedim SA is listed in Paris (EURONEXT: CGM). To learn more, please visit: www.cegedim.com

Contacts:

+--+--------------------+--------------------+--------------------+--+
|  |     Aude BALLEYDIER|Jan Eryk UMIASTOWSKI|Guillaume DE        |  |
|  |                    |                    |CHAMISSO            |  |
+--+--------------------+--------------------+--------------------+--+
|  |             Cegedim|             Cegedim|Presse & Papiers    |  |
|  |                    |                    |Agency              |  |
+--+--------------------+--------------------+--------------------+--+
|  |     Media Relations|Chief investment    |       Press Officer|  |
|  |                    |Officer Investor    |                    |  |
|  |                    |Relations           |                    |  |
+--+--------------------+--------------------+--------------------+--+
|  |                    |Tel.: +33 (0)1 49 09|                    |  |
|  |                    |33 36               |                    |  |
+--+--------------------+--------------------+--------------------+--+
|  |Tel.: +33 (0)1 49 09|investor.relations@c|Tel.: +33 (0)1 77 35|  |
|  |68 81               |egedim.fr           |60 99               |  |
+--+--------------------+--------------------+--------------------+--+
|  |aude.balleydier@cege|                    |guilaume.dechamisso@|  |
|  |dim.fr              |                    |pressepapiers.fr    |  |
+--+--------------------+--------------------+--------------------+--+
+--+--------------------+--------------------+--------------------+--+

This information is provided by HUGIN

MINNEAPOLIS, MN–(Marketwire – September 23, 2010) –  Indigo Identityware, a growing leader in the Identity & Access Management industry, has partnered with Netgain to market and deploy its software-only solution that offers Behavioral Strong Authentication, single sign-on and session management for the extended enterprise. Indigo’s secure identity management solutions, paired with Netgain’s data security and delivery, meet clinicians’ desire for increased productivity and simplicity. 

In the ever-increasing security conscious environment, healthcare providers are required to use multiple complex passwords when accessing patient records. With Indigo’s solution, it eliminates the cumbersome password process while maintaining security, allowing the doctor more time to focus on the patient.

“Our clients trust us to provide an all-encompassing solution that combines HIPAA-level security with ease of use, and we found that with Indigo. By utilizing their unique Behavioral Strong Authentication and Single Sign-on solution, providers are more productive and the patient’s experience is enhanced because doctors can focus on the patient instead of worrying about complex or forgotten passwords,” said Matt Riley, Netgain’s COO.

“We’re excited to work with an organization like Netgain, whose mission in healthcare IT so closely aligns with ours,” said John Woodward, COO and President of Healthcare for Indigo Identityware. “Our services are complementary to Netgain’s, and together we provide a complete solution that addresses a major issue for all healthcare organizations.”

About Netgain
Netgain, a privately held provider of healthcare information technology solutions, relieves the day-to-day burden of information technology operations for healthcare organizations. Netgain provides application hosting and infrastructure support with extensive technical expertise in securing sensitive data by deploying a rare combination of process excellence and personal service. 

About Indigo
Indigo Identityware, a leader in the identity and access management industry, distinguishes itself by offering the first and only Behavioral Strong Authentication and Single Sign-on solution for the extended enterprise. Indigo’s flexible design supports multiple strong authentication methods, including next generation biometrics, providing users with secure and fast access to information. It increases workflow productivity while helping customers ensure regulatory compliance. The software-only solution is cost-effective and deploys quickly for organizations of any size.  

VANCOUVER, BRITISH COLUMBIA–(Marketwire – Sept. 23, 2010) – Reduced wait times and better access to hospital services are among the benefits patients in BC’s health care system could expect with the implementation of Patient Focused Funding (PFF). In this model, patients are seen as a benefit to hospitals instead of a cost. Hospitals would be paid for every patient they treat providing the impetus to see everyone in a timely manner and increase the volume of services provided to patients. The measures used to determine success of PFF programs must be evidence-based, risk-adjusted, and developed in collaboration with patient representatives.

Recently, there have been various funding models discussed by government and other stakeholders in the quest to contain health care costs. Patient Focused Funding in this case is defined as any method of compensating providers – which can include physicians, nurses, and hospitals – that uses financial incentives to improve the appropriateness, quality, and efficiency of care for patients. The BC Medical Association has released its policy paper Valuing Quality: Patient-Focused funding in British Columbia, which offers ten recommendations on the structure, implementation and evaluation of PFF including:

• Any PFF program must be designed to support and improve the timeliness, safety, and health outcomes of patient care within a cost certain environment.
• A multi-stakeholder working group under the BC Health Services Purchasing Organization must be created and should include physicians and other health care providers.
• All PFF programs must be rigorously evaluated for their impact on patient care, access and costs.

“Our research has shown that PFF models need to be flexible and phased in to any situation in which they could be applied,” said Dr. David Attwell, Chair of the Working Group that developed the paper. “Implementation of a successful PFF program requires system-wide collaboration, commitment and leadership to achieve the highest level of quality for patients, for those who work in the health care system, and for government who pays for it.”

The BC government has recently announced its investment of $250 million, plus another $24.3 million, to launch and further develop its PFF model. Although the BC Medical Association supports many of government’s PFF initiatives, we also believe that patient safety and quality of care must be included as key measurement criteria. As well, more work needs to be done to ensure everyone involved in PFF from hospitals to health care providers to government share the same understanding of how PFF models function.

The policy paper can be found on the BCMA website at www.bcma.org.

PLYMOUTH, MN–(Marketwire – September 23, 2010) –  Hearing loss is now the third most common chronic, but manageable, health condition in the United States, after arthritis and high blood pressure, according to the Hearing Loss Association of America (HLAA). Yet, fewer than half of those with hearing loss who could benefit from hearing aids use them. “During Hearing Aid Awareness Week, October 3 – 10, we want to help everyone understand how important it is to take steps to detect and manage hearing loss early, before it has a chance to impact your quality of life and even your earning potential,” says Rebecca Younk, audiologist for Miracle-Ear.

According to the HLAA, 1 in 10 Americans experiences some type of hearing loss. And yet, fewer than half of those hearing-impaired individuals use any type of hearing aid. Why? One reason may be that hearing loss is so gradual over time, that most people don’t notice a change until it has become really pronounced. Other reasons may include embarrassment. “Even though eyeglasses and contact lenses have now become perfectly socially acceptable, we still have to work hard to ensure that hearing aid wearers are treated with the same respect as eyeglass wearers,” explains Younk.

“The impact that unmanaged hearing loss can have on your life goes way beyond missing a word in a conversation here and there,” emphasizes Younk. “Here are just a few good reasons, beyond simply enhancing your overall quality of life, to consider having a hearing test soon.”

• Hearing loss can starve the auditory centers of the brain of acoustic information, leading to auditory deprivation — and a resulting decrease in speech understanding. Hearing aids can help these auditory centers “stay busy,” to protect against this loss.
• Research available at The Better Hearing Institute (BHI) suggests that patients with unmanaged hearing loss suffer more from depression and social isolation compared to those of similar age who wear hearing aids.
• A study conducted by the BHI also suggests that hearing impaired patients choosing not to wear hearing aids earn less when compared to hearing impaired patients who choose to use hearing aids.

Today’s hearing aids offer discreet, customized hearing solutions, tailored to your lifestyle, age and activities. Miracle-Ear offers a comprehensive hearing assessment that includes a complete hearing health history, ear canal inspection, hearing threshold test and speech discrimination test. If these tests indicate a hearing loss, Miracle-Ear works with the client to determine which solution best meets his or her individual needs.

“Hearing loss is a growing problem in the U.S.,” says Younk, “but only about 13 percent of physicians routinely screen for hearing loss during a physical. You could have hearing loss and not even know it. It’s the people closest to you who may recognize it first. If your friends or family are advising you to have your hearing tested, you should listen to them!”

For more information on Miracle-Ear, please visit http://www.miracle-ear.com/.

About Miracle-Ear
A trusted resource for hearing solutions for over 60 years, Miracle-Ear uses state-of-the-art technology to remove the barriers of hearing loss. The Plymouth, Minn.-based company specializes in customizable hearing solutions that feature discreet, comfortable products designed to meet each individual’s hearing loss needs. Free hearing tests and consultations are available at all of the company’s 1,200 locations across the U.S., many of which are in Sears stores. Franchise opportunities are available for those interested in running their own Miracle-Ear business with the support of a nationwide industry leader. 

For more information, visit www.miracle-ear.com. 

SAN FRANCISCO, CA–(Marketwire – September 23, 2010) –  Medizone International, Inc. (OTCBB: MZEI) (OTCQB: MZEI) announced today the Company has filed a fourth U.S. Provisional patent application involving what it terms, “Advanced Oxidative Sterilization Processes.”

Dr. Michael Shannon, Director of Medical Affairs, explained, “We are now exploring a new development in the field of oxidative chemistry which we believe will have a significant impact on our future technology and the ease with which we can effectively decontaminate hospitals, chronic care facilities, veterinary facilities, hotels, cruise ships, sports facilities and the equipment therein. Our research to date clearly demonstrates that the combination of modest levels of ozone and low concentrations of peroxide, properly delivered at the right temperature and humidity, will reliably eliminate bacterial loads of at least 6 logs (sterilization standard) on a broad range of surface materials, including carpets, for all of the ‘Superbugs’ responsible for Hospital Acquired Infections. This new development, however, further enhances Medizone’s AsepticSure™ technology in a manner not anticipated. In fact, decontamination in the future will very likely be based on unique combinations of what we are calling ‘Advanced Oxidative Sterilization Processes’ which build on the existing technology by using a family of chemical moieties considered to be even more potent than either ozone or peroxide to destroy a broad range of potentially lethal pathogens. Research is now underway at our laboratories in Kingston on a parallel track with our hospital beta testing program to evaluate the merits of a multifactorial decontamination system which appears to further increase the potency of AsepticSure™ while dramatically reducing the exposure time, both of which have major implications for certain applications.”

Medizone’s CEO, Edwin Marshall, added, “With two international patent applications filed in addition to the four U.S. provisional applications now in place, we are taking the steps we believe necessary to fully protect the commercial rights of Medizone International. It is now clear that what began as a technology to decontaminate and sterilize hospital spaces has grown into the foundations of an entirely new sterilization industry. We are developing a family of solutions based on the nuances of specific applications. Given the outcomes of recent meetings with both private industry players and government, it is clear we are not alone in recognizing this concept. As I announced in a recent interview with Don Baillargeon for a segment of his show, ‘MoneyTV,’ to be aired this coming Saturday, we have even filed a patent application addressing the bed bug issue for the cruise ship and hotel industry. We are not making too much of it yet, as the science for that application remains to be completed. However, we are guardedly optimistic that we will be able to provide an effective and affordable solution to that market segment as well, and thus wanted to get the IP protection in place as soon as possible.”

Medizone International, Inc. is a research and development company engaged in developing its AsepticSure™ System to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. A government variant is being developed for bio-terrorism counter measures with additional variants for sports facilities and food processing applications and, potentially, the hotel and cruise ship industry for bed bug eradication and Norwalk virus.

This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

Click here to see all recent news from this company

TORONTO, ONTARIO–(Marketwire – Sept. 23, 2010) –

Editors Note: A photo for this release will be available via Marketwire on the picture wire of The Canadian Press.

Ornge, a world leader in the field of transport medicine, is proud to introduce the most significant fleet upgrade in the history of aero medical transport in Ontario. The first of the new AgustaWestland AW139 helicopters were unveiled this morning at the Ornge base at the Billy Bishop Toronto City Airport. The new helicopters will transport Ornge’s medical teams who provide services for patients requiring advanced and critical levels of care during transport.

Ornge paramedics and pilots employed by CHL, the operator of Ornge rotor aircraft, will begin transporting patients in the new high-performance medium twin turbine helicopters over the coming months. Ornge purchased ten AW139 aircraft from AgustaWestland, a Finnmeccanica company, in 2008 to replace the older fleet of Sikorsky S76 helicopters currently in use at Ornge bases across the province. 

“As innovators in our field, we are on the cutting edge of both aviation and medicine,” said Dr. Christopher Mazza, Ornge CEO and Emergentologist. “The AW139 medically-equipped aircraft will help us to deliver a modern, high quality, sustainable transport medicine program for Ontario patients today and for generations to come.”

The AW139 is the most technologically advanced rotor wing aircraft in air medical transport today. The fastest helicopter in its class, it is capable of operating in a wide variety of weather conditions – from extreme heat to extreme cold – found across Ontario’s one million square kilometers. Ornge is the first AgustaWestland client in North America to have a full ice protection installed in medically equipped helicopters. The AW139 also has enhanced safety and environmental features.

Giuseppe Orsi, Chief Executive Officer, AgustaWestland said: “We are proud to be part of this new era in transport medicine in Ontario providing the best medium twin helicopter to such a leading operator and to the benefit of the large community they serve. The AW139 will enable Ornge to perform a quantum leap forward in operational capability to successfully accomplish the mission and save lives in the harshest conditions when other models would be confined to the hangar.”

Each helicopter is outfitted with an advanced full medical interior designed and configured by Ornge transport medicine physicians and paramedics in collaboration with Aerolite, a world leader in medical helicopter and fixed-wing aircraft interiors. 

In January 2006, Ornge began coordinating all aspects of the province’s transport medicine system. Since then, Ornge has transported nearly 95,000 patients more than 30 million statute miles – over 1,200 times around the earth — in its rotor and fixed wing aircraft, along with its critical care land units.

ABOUT ORNGE

Ornge is the world’s leading innovator in the emerging field of transport medicine, and operates from a number of bases across the province of Ontario and performs more than 20,000 admissions annually. It coordinates all aspects of Ontario’s aero medical transport system, the new critical care land transport program, paediatric transport program and the authorization of air and land ambulance transfers between hospitals. Ornge is dedicated to the provision of high quality patient care through innovative transport medicine.

ABOUT AGUSTAWESTLAND

AgustaWestland, a Finmeccanica company, is a technology leader in its markets and has an unrivalled range of rotorcraft products designed to satisfy the requirements of commercial and military customers. AgustaWestland has its main operations in Italy, the United Kingdom and the United States of America.

ATLANTIC CITY, NJ–(Marketwire – September 23, 2010) – GetWellNetwork, Inc., today announced that David Wright, the Company’s chief outcomes officer, will address the New Jersey and Delaware chapters of HIMSS on how hospitals can strengthen their position in the “Pay for Performance” provisions of the new health care reform law. The fall regional health information symposium is being held from September 22-24th at the Atlantic City Caesars Hotel and Casino.

Mr. Wright will share with attendees how the “Pay for Performance” model impacts the quality measurements that are being evaluated in the Patient Protection and Affordable Care Act’s Value-Based Purchasing and Accountable Care Organizations programs. “Pay for Performance” programs measure a variety of performance indicators such as clinical processes of care, health outcomes, patient safety, patient experience and satisfaction, and information technology investment and use.

Mr. Wright will also explain how leading hospitals and health systems are using interactive patient care technology to achieve evidence-based outcomes and to improve hospital performance in these areas that directly impact “Pay for Performance” provisions.

Without a clear outcomes plan and technology solution in place, hospitals may see dramatic reductions in their Medicare reimbursements as early as October 2012 with payments made based on 2011-2012 performance(1). Using best practices and practical examples from leading hospitals, Mr. Wright will provide insights that will help hospitals formulate their own plans to become “high performers” in the era of health care reform.

“The regional HIMSS conference provides an opportunity to address the key issues hospitals must consider for implementing initiatives that affect the patient care factors of the Pay for Performance provision,” said David Wright, chief outcomes officer, GetWellNetwork, Inc. “To ensure continuation of maximum reimbursements from the Federal government, all hospitals need to have a core strategy that helps them excel in the new performance measurements that will be used to calculate their effectiveness in patient treatment.”

About GetWellNetwork
GetWellNetwork, Inc. uses the bedside TV to entertain, educate and empower hospital patients and caregivers to be more actively engaged in their care. This patient-centered approach improves both satisfaction and outcomes for patients and hospitals. GetWellNetwork is the leader in interactive patient care solutions and exclusively endorsed by the American Hospital Association. More information about GetWellNetwork can be found at www.GetWellNetwork.com.

(1) More information about CMS’ Value-Based Purchasing Program is available at http://www.cms.gov/AcuteInpatientPPS/downloads/HospitalVBPPlanRTCFINALSUBMITTED2007.pdf and http://www.cms.gov/QualityInitiativesGenInfo/downloads/VBPRoadmap_OEA_1-16_508.pdf

Click here to see all recent news from this company

SOUTH SAN FRANCISCO, CA–(Marketwire – September 23, 2010) – Portola Pharmaceuticals, Inc. today announced the appointment of Jean-Jacques Bienaimé to the company’s board of directors. Mr. Bienaimé currently serves as chief executive officer of BioMarin Pharmaceutical Inc. He is chairman of the board of NeurogesX, Inc., a member of the board of BIO and a member of the advisory board of Bellevue Asset Management’s BioVentures II fund.

“Jean-Jacques Bienaimé is a biotechnology and pharmaceutical industry veteran with more than 25 years of experience,” said William Lis, chief executive officer of Portola. “His experience as a CEO managing and building fully integrated biotechnology companies and his expertise commercializing anti-thrombotic products will be invaluable to Portola as we advance our two lead partnered product candidates, elinogrel and betrixaban, and our pipeline of proprietary products in cardiovascular disease and inflammation through clinical development and into commercialization.”

Mr. Bienaimé joined BioMarin, which develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, in May 2005 as chief executive officer and member of the board of directors. Prior to joining BioMarin, he served as chairman, chief executive officer and president of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics. Before that, he served as chairman, chief executive officer and president of Sangstat Medical Corporation, an immunology-focused biotechnology company that he guided to profitability prior to its acquisition by Genzyme Corporation. Earlier in his career, Mr. Bienaimé held several senior management positions at Rhone-Poulenc Rorer Pharmaceuticals (now sanofi-aventis) culminating in the position of senior vice president of worldwide marketing and business development responsible for, among other things, the launch of Lovenox^® (for the prevention of pulmonary embolism and treatment of unstable angina) in the United States. He also worked at Genentech, Inc. where he was involved in the launch of tissue plasminogen activator (t-PA) for the treatment of heart attacks.

He received an M.B.A. from the Wharton School at the University of Pennsylvania and an undergraduate degree in economics from the École Supérieure de Commerce de Paris.

About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals develops innovative therapeutics based on targets with established proofs of concept that are designed to provide significant advances over current treatments for cardiovascular disease and inflammation. The company has global development and commercialization agreements with two of the world’s leading pharmaceutical companies collectively valued at about $1 billion in upfront and milestone payments plus double-digit royalties on future sales. Betrixaban, its oral direct Factor Xa inhibitor, is licensed to Merck & Co., Inc., and elinogrel, its competitive, reversible P2Y₁₂ ADP receptor antagonist, is licensed to Novartis Pharma AG. Both are Phase 2 product candidates that have features to address the global multi-billion dollar hospital, specialty and chronic care anticoagulant and antiplatelet markets, respectively.

Portola’s proprietary pipeline programs are focused on the discovery and development of PRT061103, a thromboxane receptor antagonist, which is targeted to address a significant unmet need as a potential aspirin alternative for patients intolerant to aspirin; PRT064445, a Factor Xa inhibitor antidote to help manage or reverse the bleeding complications in the tens of millions of patients expected to be treated with Factor Xa inhibitors or low-molecular weight heparin worldwide in the next decade; and PRT062607, a novel, oral Syk-specific kinase inhibitor to treat chronic inflammatory diseases, including rheumatoid arthritis, and certain cancers, including non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. For additional information, visit www.portola.com.

LAUSANNE, SWITZERLAND–(Marketwire – September 23, 2010) –  

• 40 patients enrollment completion
• Positive preliminary results

Symetis SA, a private Swiss company developing new transcatheter aortic valve implantation (TAVI) systems, announced today the completion of patient enrollment in its ACURATE TA™ first-in-man (FIM) clinical study and positive preliminary results. ACURATE TA™ is a self-aligning nitinol stent valve designed for optimal trans-apical delivery, providing the physician with unmatched positioning tolerance and ease of use.

Details of the study
The study — the largest 2nd generation TAVI FIM study ever conducted — was conducted at 5 sites in Germany: Leipzig Herzzentrum, Kerckhoff-Klinik Bad Nauheim, Freiburg UniversitätsSpital, Westdeutsches Herzzentrum Essen and Universitäres Herzzentrum Hamburg. Forty (40) patients with severe aortic stenosis were recruited and treated with ACURATE TA™. The average age of treated patients was 83 years with a mean Logistic EuroScore of 21.5% and STS Score of 9.0%.

Results
Successful valve implantation with the ACURATE TA™ occurred in 38 patients (95.0%). One patient received a valve-in-valve using a commercially available transapical valve and one patient was converted to sAVR. Only one patient required a new pacemaker post-implant. 30-day mortality was 12.5% including 3 deaths from non-valve-related respiratory complications. Comprehensive 30-day results will be presented at the Dallas / Leipzig International Valve conference in December 2010.

Dr. Joërg Kempfert of Leipzig Herzzentrum commented: “The ACURATE TA™ is truly intuitive, easy to use, reliable and covers the full spectrum of severe aortic stenosis. We look forward to the Pilot study to confirm the excellent results obtained in this comprehensive FIM study.”

Laura Brenton, VP Clinical / Regulatory Affairs, added: “The ease of use of the ACURATE TA™ was acknowledged by all physicians participating in the study. Additionally, the learning curve was significantly shorter than that of competitive systems. Furthermore, the robust size of the FIM allows for comparison of its initial data to published statistics from competitors suggesting comparable or improved initial outcomes.”

Jacques R. Essinger, CEO of Symetis, added: “ACURATE™ TA is the second generation TAVI system with the largest clinical experience to date. We are building on this competitive advantage by soon beginning a pilot clinical study, a major step toward achieving European compliance and the CE mark.”

About Symetis
Symetis SA (www.symetis.com) is a private Swiss company developing innovative, minimally invasive heart valve replacement solutions. Symetis’s Acurate TA™ system, based on proprietary geometry and delivery technology, is in clinical trials and is well positioned to target the ca. $2 billion transcatheter aortic valve implantation (TAVI) market. The company is financed by leading European venture capital firms including Truffle Capital, Novartis Venture Fund, Aravis Venture, Wellington Partners, Vinci Capital, Banexi Venture and BiomedInvest.